 WOODCLIFF LAKE, N.J.--BUSINESS WIRE--Eagle Pharmaceuticals, Inc. Nasdaq: EGRX Eagle or the Company today announced that it has entered into a licensing agreement with AOP Orphan Pharmaceuticals GmbH AOP Orphan, a privately owned Austrian company devoted to the treatment of rare and special diseases, for the commercial rights to its product, Landiolol in the United States. Landiolol, a leading hospital emergency use product, is currently approved in Europe for the treatment of non- 